Mr. Arkowitz joined our board of directors in 2014. Mr. Arkowitz brings more than 25 years of finance and operations leadership experience in the life sciences and biotechnology industries. He currently serves as the Chief Financial Officer of Flexion Therapeutics Inc. Prior to joining Flexion, he served as Chief Operating Officer and CFO at Visterra, Inc. (which was acquired by Otsuka Pharmaceuticals Co.), where he led the finance, business development, corporate planning, and other functions. Previously, he was CFO at Mascoma Corporation, AMAG Pharmaceuticals and Idenix Pharmaceuticals and held additional leadership positions within each company. Preceding his tenure at Idenix, Mr. Arkowitz spent more than 13 years at Merck & Co., Inc. where he held roles of increasing responsibility, including Vice President and Controller of the U.S. operations, Controller of the global research and development division, and CFO of the Canadian subsidiary. Mr. Arkowitz also serves on the board of directors of Proteostasis Therapeutics, Inc., a publicly traded biotechnology company. He holds a BA in mathematics from Brandeis University and a MBA in finance from Columbia University Business School.
Todd Brady, M.D., Ph.D.
Dr. Brady joined our board of directors in 2016. Dr. Brady has served as the President and Chief Executive Officer of Aldeyra Therapeutics, Inc. since 2012. Dr. Brady also served as Entrepreneur in Residence at Domain Associates, LLC, a leading healthcare venture capital firm, from 2004 to 2013. Prior to joining the firm as a Principal in 2004, Dr. Brady held senior leadership positions at Aderis Pharmaceuticals, Inc., Xanthus Life Sciences, Inc., and Phenome Sciences. Dr. Brady also serves on the board of directors of Aldeyra Therapeutics, Inc. and Evoke Pharma, Inc. and numerous other privately traded biotechnology companies. Dr. Brady holds a Ph.D. in pathology from Duke University Graduate School, a M.D. from Duke University Medical School, and an A.B. from Dartmouth College in Philosophy and Psychology.
Timothy Clackson, Ph.D.
Dr. Clackson joined our board of directors in 2018. Dr. Clackson currently serves as President and Executive Vice President of Research and Development of Akrevia Therapeutics. Previously, Dr. Clackson served as president of research and development at ARIAD Pharmaceuticals, Inc. until its acquisition by Takeda. He led the R&D team that discovered and brought to market two innovative targeted therapies for cancer and moved three additional medicines into clinical development. Prior to his seven years as president of R&D, Dr. Clackson served as ARIAD’s senior vice president and chief scientific officer. Dr. Clackson was a postdoctoral fellow at Genentech, Inc. from 1991 to 1994 prior to his joining ARIAD in December 1994. Dr. Clackson currently serves on the board of directors of MassBio. He holds a B.A. in biochemistry from the University of Oxford, and a Ph.D. in biology from the University of Cambridge.
Mr. Driscoll joined Spring Bank in 2015 as President, Chief Executive Officer and Director. Previously, he served as CEO of Asmacure Ltée, a venture-backed, clinical-stage biopharmaceutical company which he joined in late 2010. Asmacure Ltée was acquired by a privately-held Canadian life sciences company in July 2015. Prior to Asmacure, Mr. Driscoll was the CEO and a director of Javelin Pharmaceuticals, Inc., a publicly-traded developer of acute care pain products, from March 2008 until July 2010, when he engineered the merger of Javelin with Hospira, Inc. He also served in various senior management roles at Schering-Plough Corporation, ViroPharma, Inc. and Reliant Pharmaceuticals, Inc. In 2007, Mr. Driscoll co-founded Pear Tree Pharmaceuticals, Inc., a privately-held developer of women’s healthcare products. He has been involved with or led the commercialization of several important therapies, the direct negotiation of numerous licensing and M&A transactions, multiple private and public capital fundraising efforts and the successful submission of major product regulatory filings. He also served as a director on the boards of four private and public biopharmaceutical development companies and currently serves on the board of Asmacure Ltée. Mr. Driscoll holds a BSc in communications from the University of Texas at Austin. He is a trustee of the Barn for the Poorest of the Poor, a non-profit food pantry based in New Jersey.
Kurt M. Eichler
Mr. Eichler joined our board of directors in 2015. Since his retirement from The Linpro Company (now LCOR, Inc.), a private real estate investment and development company specializing in complex urban development, in 2013, Mr. Eichler has been self-employed in several real estate related investment and development ventures. Mr. Eichler joined LCOR as Director of Commercial and Industrial Operations for the suburban Philadelphia area, and later served as the Operating Partner in the Center City Philadelphia Office. Mr. Eichler also served as Executive Vice President and Principal of LCOR in charge of operations of the metropolitan New York region. Based in New York City, Mr. Eichler served on LCOR’s Executive Committee. Mr. Eichler began his career at Merrill Lynch Hubbard Inc. in the Real Estate Debt and Equity Finance Group. He has served on several boards over the last decade including Dara Biosciences, Inc., MiMedx Group, Inc. and Maia Yogurt. Mr. Eichler holds a BS from the University of Wyoming.
Pamela Klein, M.D.
Dr. Klein joined our board of directors in July 2019. She is a principal and founder of PMK BioResearch, which offers strategic consulting in oncology drug development to corporate boards, management teams and the investment community. She previously served as Chief Medical Officer of Intellikine, which was acquired by Takeda Pharmaceuticals in 2011, and Vice President, Development, at Genentech. Dr. Klein also spent seven years at the National Cancer Institute as Research Director of the NCI-Navy Breast Care Center. Dr. Klein currently serves as a member of various scientific advisory boards as well as on the board of directors of argenx SE, a biotechnology company. Dr. Klein holds a B.A. in biology from California State University and an M.D. from Stritch School of Medicine, Loyola University Chicago, and is trained in internal medicine and medical oncology.
Mr. Smith joined our board of directors in August 2018 and was appointed as chairman of our board of directors effective January 1, 2019. Mr. Smith currently serves as the President of Bioalta, LLC. Mr. Smith previously served as president and chief operating officer at Celgene Corporation. From 2010 through 2017, Mr. Smith served as an executive vice president and president of Inflammation & Immunology at Celgene. Under his leadership, the Inflammation & Immunology franchise at Celgene developed into a global business with more than a billion dollars in revenue. Prior to joining Celgene in 2008, he was a vice president & general manager and head of strategic marketing and business analysis at Biovail Pharmaceuticals, Inc. He currently serves on the board of directors of Titan Pharmaceuticals and Triumvira Immunologics, Inc. He holds a B.S. degree in Chemistry and Biology and an Honors B.S. degree in Toxicology and Pharmacology from the University of Western Ontario and his Master’s degree in International Management from the American Graduate School of International Management in Glendale, AZ.